Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series Ltd: World’s leading Event Organizer
Vaccine development generally involves a lot of work on the antigen aspect, some effort on formulation, and the addition of an adjuvant in some form or another. These components are often elaborated separately and delivered as a mixture, sometimes in an emulsion or in a liposome, with the hope that some fraction of the material administered gets to the right place. Recent work on materials engineering at MIT has brought together novel assemblies of lipid nano particles loaded with antigen and adjuvant, “hardened” by chemical cross-links to create a system that co-delivers its payload to lymph nodes. We call these particles ICMVs (Inter-bilayer Cross-Linked Multi-Lamellar Vesicles. By sequestering the adjuvant and antigen in a particle, systemic exposure is limited. This should result in an improved safety and tolerability profile. In mice, the optimal dose of antigen is on the order of a microgram. Adjuvants, engineered to fit into the nano particle, allow the use of very low doses as well. The result is a potent, long lasting humoral response accompanied by a robust antigen specific CD8+ T-cell response. ICMVs can be delivered by injection, but they may delivered by inhalation as well. Intratracheal delivery to the lungs results in a strong CD8+ response on mucosal surfaces with no apparent pathology. The application of ICMV mediated malaria vaccines will be discussed.
OMICS International 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in 2012 to $43.4 billion in 2017 at a compound annual growth rate (CAGR) of 5.3%.An overview of the global market for human and animal (veterinary) vaccines and related vaccine technologies. Analyses of global market trends, with data from 2010, 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017. Examination of current and future strategies within the human and animal (veterinary) vaccines markets, including attenuated (live) vaccines, inactivated (killed) vaccines, conjugate vaccines, recombinant/recombinant DNA (rDNA) vaccines, subunit vaccines, toxoid vaccines, and combination vaccines. A breakdown of the seven major categories of vaccines broken down by market shares belonging to leading manufacturers and/or suppliers. Discussion of human and animal (veterinary) vaccines as to their prophylactic or therapeutic use, with emphasis in the meningococcal/pneumococcal vaccines, influenza vaccines, pediatric vaccines, adult/adolescent vaccines, and travel vaccines.
Relevant societies and associations:
This page will be updated regularly.
This page was last updated on 14th Sep, 2015
1-702-508-5200 Ext:8031, 8041
1-702-508-5200 Ext:8045, 8047
Immunology & Microbiology Conferences
Nursing and Healthcare Conferences
Clinical and Biochemistry Conferences
1-702-508-5200 Ext:8031, 8037
Material Science Conferences
Genetics & Mol Biology Conferences
Media Partners | Advertising